These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
649 related articles for article (PubMed ID: 28373759)
21. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease. Farkas K; Molnár T Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994 [TBL] [Abstract][Full Text] [Related]
22. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382 [TBL] [Abstract][Full Text] [Related]
23. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Pouillon L; Bossuyt P; Peyrin-Biroulet L Expert Opin Biol Ther; 2016 Oct; 16(10):1277-90. PubMed ID: 27329436 [TBL] [Abstract][Full Text] [Related]
24. [Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?]. Schreiber S Z Rheumatol; 2015 Oct; 74(8):689-94. PubMed ID: 26450434 [TBL] [Abstract][Full Text] [Related]
25. Biosimilars: biologics that meet patients' needs and healthcare economics. McCamish M; Yoon W; McKay J Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221 [TBL] [Abstract][Full Text] [Related]
27. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. Isaacs JD; Cutolo M; Keystone EC; Park W; Braun J J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380 [TBL] [Abstract][Full Text] [Related]
28. Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease. Bhat S; Limdi JK; Cross RK; Farraye FA Dig Dis Sci; 2021 Aug; 66(8):2513-2532. PubMed ID: 34176024 [TBL] [Abstract][Full Text] [Related]
29. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Haghnejad V; Le Berre C; Dominique Y; Zallot C; Guillemin F; Peyrin-Biroulet L Dig Liver Dis; 2020 Mar; 52(3):281-288. PubMed ID: 31648920 [TBL] [Abstract][Full Text] [Related]
30. [New molecules in the treatment of inflammatory bowel disease]. Chaparro M; Gisbert JP Gastroenterol Hepatol; 2016; 39(6):411-23. PubMed ID: 26631943 [TBL] [Abstract][Full Text] [Related]
32. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. Avila-Ribeiro P; Fiorino G; Danese S Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114 [TBL] [Abstract][Full Text] [Related]
33. Clinical trial development for biosimilars. Alten R; Cronstein BN Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550 [TBL] [Abstract][Full Text] [Related]
34. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. Gisbert JP; Chaparro M Gastroenterol Hepatol; 2018; 41(6):389-405. PubMed ID: 29753532 [TBL] [Abstract][Full Text] [Related]
35. Biosimilars of adalimumab: the upcoming challenge in IBD. Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098 [No Abstract] [Full Text] [Related]
36. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13. Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530 [TBL] [Abstract][Full Text] [Related]
37. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. Scott BJ; Klein AV; Wang J J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228 [TBL] [Abstract][Full Text] [Related]
38. Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease? Buer L; Høivik ML; Medhus AW; Moum B Dig Dis; 2017; 35(1-2):74-82. PubMed ID: 28147370 [TBL] [Abstract][Full Text] [Related]
39. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD). Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F; Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575 [No Abstract] [Full Text] [Related]
40. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Reinisch W; Louis E; Danese S Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]